Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Febrile Neutropenia 7Neoplasms 5Hematologic Neoplasms 3Neutropenia 2Fever 2Urinary Bladder Neoplasms 1Sepsis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Other Infectious Diseases 1Leukemia, Myeloid, Acute 1Emergencies 1

Interventions

Cyclophosphamide 413Methotrexate 250Cytarabine 235Vincristine 192fludarabine phosphate 174Dexamethasone 171fludarabine 147Etoposide 143Peripheral Blood Stem Cell Transplantation 137Filgrastim 132Whole-Body Irradiation 118Mycophenolic Acid 116Busulfan 113Doxorubicin 110Mercaptopurine 108Tacrolimus 107Cyclosporine 95Radiotherapy 93Melphalan 93pegaspargase 90Rituximab 90Prednisone 87Asparaginase 87Daunorubicin 86Granulocyte Colony-Stimulating Factor 76blinatumomab 74Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Meropenem × Clear all
NCT05784844 2024-09-19

Antimicrobial Revision in Persistent Febrile Neutropenia

Wake Forest University Health Sciences

Phase 4 Withdrawn
Classical hematologyLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡